---
title: Persistent Atrial Fibrillation Ablation and Correlation to Quality of Life
nct_id: NCT04290559
overall_status: UNKNOWN
sponsor: Newmarket Electrophysiology Research Group Inc
study_type: OBSERVATIONAL
primary_condition: Atrial Fibrillation
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04290559.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04290559"
ct_last_update_post_date: 2020-03-31
last_seen_at: "2026-05-12T06:58:25.413Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Persistent Atrial Fibrillation Ablation and Correlation to Quality of Life

**Official Title:** Long-term Monitoring After Persistent Atrial Fibrillation Ablation and Correlation to Quality of Life

**NCT ID:** [NCT04290559](https://clinicaltrials.gov/study/NCT04290559)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Newmarket Electrophysiology Research Group Inc
- **Conditions:** Atrial Fibrillation
- **Start Date:** 2018-09-10
- **Completion Date:** 2022-09
- **CT.gov Last Update:** 2020-03-31

## Brief Summary

The primary objective of this study is to determine the atrial fibrillation burden reduction, or absolute atrial fibrillation burden, associated with improvement in quality of life in patients undergoing ablation of persistent atrial fibrillation.

## Detailed Description

Atrial fibrillation (AF) is associated with a higher risk of stroke, heart failure and deterioration in patients' quality of life and it also has great effect on health care resource utilization due to increasing morbidity and mortality. Catheter ablation has shown to improve patients' quality of life (QOL), even in those who undergo a repeat procedure, equalizing healthy population and lowering subsequent health care resource utilization.

Success rates are usually based on an endpoint of total elimination of AF, typically absence of any AF recurrence \>30 seconds. While this is a high standard for clinical trial reporting, it does not necessarily measure the "clinical" success, since many patients will experience significant reduction in their AF burden with accompanying improvement in their functional status despite having ongoing brief recurrences of AF.

This is a prospective non-randomized, single-arm, cohort study. 200 patients with persistent atrial fibrillation undergoing catheter ablation will be enroled. AF burden post procedure will be evaluated with continuous monitoring with an implantable loop recorder (ILR) to assess recurrences and AF burden. QOL will be measured using the CCS-SAF severity scale, SF-36 and AFEQT scales pre-ablation and at 12 and 24 months.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age \> 18 years
* Patients undergoing first-time or redo AF ablation.
* Persistent or long-standing persistent AF
* Symptomatic atrial fibrillation
* Willing and able to provide informed consent.
* Willing and able to set up and utilize MyCareLink® home monitor and be remotely monitored
* Atrial fibrillation burden equal or more than 80% prior to the ablation

Exclusion Criteria:

* Paroxysmal AF
* If the patient has had a cardioversion within 2 months of the ablation
* Patients with contraindication to oral or intravenous anticoagulation.
* Contraindication to implantation of an ILR
```

## Interventions

- **Reveal LINQ ILR implant before AF ablation** (PROCEDURE) — Patients will undergo insertion of a LINQ ILR before the atrial fibrillation ablation performed according to standard clinical practice.

## Primary Outcomes

- **AF burden correlated with change in QOL.** _(time frame: 12 months, 24 months)_ — AF burden change and absolute AF burden correlated with change in QOL mesured at 12 and 24 months after the AF ablation

## Secondary Outcomes

- **Freedom of atrial arrhythmia** _(time frame: 12 months, 24 months)_
- **Economic evaluation** _(time frame: 12 months, 24 months)_
- **Incidence of silent AF recurrences** _(time frame: 12 months, 24 months)_
- **Impact of antiarrhythmic treatment** _(time frame: 12 months)_

## Locations (1)

- Southlake Regional Health Centre, Newmarket, Ontario, Canada — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.southlake regional health centre|newmarket|ontario|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04290559.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04290559*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*